PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy
- PMID: 1714497
PET studies of fluorodeoxyglucose metabolism in patients with recurrent colorectal tumors receiving radiotherapy
Abstract
Forty-four patients with recurrent colorectal carcinoma were examined prior to a combination of conventional photon radiotherapy (40 Gy) and neutron therapy (10 Gy). Twenty-one of these underwent a PET examination after photon therapy and 12 also were studied after the end of combined therapy. CEA plasma levels were measured from blood samples taken immediately before the PET study. A significant decrease in FDG uptake despite good palliative results were observed in only 50% of the patients. This may be explained by inflammatory reactions caused by radiation injury. Inflammation and metabolically active residual tumor tissue cannot be distinguished. It is concluded that an observation interval longer than 6 mo may more effectively detect residual tumor activity. In 14 of 41 examinations, an increased FDG uptake was associated with a normal CEA value, and in only two cases were normal FDG uptake values and increased CEA levels found, suggesting that PET is more sensitive than the measurements of CEA plasma levels for tumor recurrence.
Similar articles
-
Utility of FDG-PET for investigating unexplained plasma CEA elevation in patients with colorectal cancer.Ann Surg. 1998 Mar;227(3):319-23. doi: 10.1097/00000658-199803000-00001. Ann Surg. 1998. PMID: 9527052 Free PMC article.
-
Photon-neutron therapy for recurrent colorectal cancer--follow up and preliminary results.Strahlenther Onkol. 1990 Jan;166(1):95-8. Strahlenther Onkol. 1990. PMID: 2300891
-
Detection of primary and recurrent lung cancer by means of F-18 fluorodeoxyglucose positron emission tomography (FDG PET).J Thorac Cardiovasc Surg. 1995 Jul;110(1):130-9; discussion 139-40. doi: 10.1016/S0022-5223(05)80018-2. J Thorac Cardiovasc Surg. 1995. PMID: 7609536
-
Diagnosis of recurrent brain tumor: value of 201Tl SPECT vs 18F-fluorodeoxyglucose PET.AJR Am J Roentgenol. 1994 Dec;163(6):1459-65. doi: 10.2214/ajr.163.6.7992747. AJR Am J Roentgenol. 1994. PMID: 7992747
-
Therapy monitoring of presacral recurrences after high-dose irradiation: value of PET, CT, CEA and pain score.Strahlenther Onkol. 1992 Apr;168(4):203-12. Strahlenther Onkol. 1992. PMID: 1574769
Cited by
-
A Preliminary Study to Use SUVmax of FDG PET-CT as an Identifier of Lesion for Artificial Intelligence.Front Med (Lausanne). 2021 Apr 28;8:647562. doi: 10.3389/fmed.2021.647562. eCollection 2021. Front Med (Lausanne). 2021. PMID: 33996855 Free PMC article.
-
Multicentre assessment and monitored use of [(18)F]FDG-PET in oncology: the Spanish experience.Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):296-304. doi: 10.1007/s00259-007-0502-6. Epub 2007 Oct 3. Eur J Nucl Med Mol Imaging. 2008. PMID: 17912525
-
Carbon-11-methionine positron emission tomography imaging of chordoma.Skeletal Radiol. 2004 Sep;33(9):524-30. doi: 10.1007/s00256-004-0815-5. Epub 2004 Jul 28. Skeletal Radiol. 2004. PMID: 15483754
-
Evaluation of the treatment response of lung cancer with positron emission tomography and L-[methyl-11C]methionine: a preliminary study.Eur J Nucl Med. 1993 Jun;20(6):495-501. doi: 10.1007/BF00175162. Eur J Nucl Med. 1993. PMID: 8393404
-
Monitoring the neoadjuvant therapy response in gynecological cancer patients using FDG PET.Eur J Nucl Med Mol Imaging. 2008 Feb;35(2):287-95. doi: 10.1007/s00259-007-0627-7. Epub 2007 Oct 18. Eur J Nucl Med Mol Imaging. 2008. PMID: 17943281
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical